Reshape Lifesciences (RSLS) & Presbia (LENS) Head-To-Head Analysis
Reshape Lifesciences (NASDAQ: RSLS) and Presbia (NASDAQ:LENS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.
Institutional & Insider Ownership
20.8% of Reshape Lifesciences shares are held by institutional investors. Comparatively, 15.5% of Presbia shares are held by institutional investors. 26.4% of Reshape Lifesciences shares are held by company insiders. Comparatively, 74.7% of Presbia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Reshape Lifesciences has a beta of 2.68, indicating that its stock price is 168% more volatile than the S&P 500. Comparatively, Presbia has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Reshape Lifesciences and Presbia, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Reshape Lifesciences presently has a consensus price target of $11.00, indicating a potential upside of 643.24%. Presbia has a consensus price target of $9.67, indicating a potential upside of 277.60%. Given Reshape Lifesciences’ higher possible upside, equities research analysts plainly believe Reshape Lifesciences is more favorable than Presbia.
This table compares Reshape Lifesciences and Presbia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Reshape Lifesciences and Presbia’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Reshape Lifesciences||$790,000.00||56.13||-$23.36 million||($5.90)||-0.25|
Presbia has lower revenue, but higher earnings than Reshape Lifesciences. Presbia is trading at a lower price-to-earnings ratio than Reshape Lifesciences, indicating that it is currently the more affordable of the two stocks.
Reshape Lifesciences beats Presbia on 7 of the 13 factors compared between the two stocks.
About Reshape Lifesciences
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.